APTO News and Press, Aptose Biosciences Inc. From 03/04/19

The Australian Patent Office has issued Aptose Biosciences (NASDAQ: APTO ) Patent No. 2013371146 for CG-806, a pan-FLT3/pan-BTK multi-cluster kinase inhibitor developed for acute myeloid leukemia (AML), B cell and other hematologic malignancies. This small molecule is in-licensed from Crys...

SAN DIEGO and TORONTO and SEOUL, March 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that the Australian Patent Office (“APO”) has issued Australian Patent No. 2013371146 f...

CORAL GABLES, FL / ACCESSWIRE / March 1, 2019 / The healthcare stock market takes its cues from companies in the healthcare industry, and because these companies have shown impressive growth in the first few months of the new year, the surrounding market has responded favorably. Perhaps th...

SAN DIEGO and TORONTO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today anno...

SAN DIEGO and TORONTO, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of...

Aptose Biosciences (NASDAQ: APTO ) has submitted an IND application for CG-806 to the FDA requesting approval to initiate its Phase 1 clinical trial program. More news on: Aptose Biosciences Inc., Healthcare stocks news, Stocks on the move, Read more ...

SAN DIEGO and TORONTO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has submitted an Investigational New Drug (IND) application for CG-806 to the U.S. Food and Drug Adminis...

SAN DIEGO and TORONTO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President...

Rand Capital (NASDAQ: RAND )  +40%  on announcing $25M strategic investment by east asset management and establishment of external management structure. More news on: Rand Capital, ClearOne, Inc., Aptose Biosciences Inc., Stocks on the move, , Read more ...

NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The TJX Companies, Inc. (NYSE:TJX), Nasdaq, Inc. (NASDAQ:NDAQ), Werner En...